About Kearny Venture Partners
Kearny Venture Partners is a venture capital firm founded in 2000. It is primarily based out of San Francisco, United States. As of Mar 2017, Kearny Venture Partners has invested in 23 companies. It primarily invests in Series C round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Series C round of Aerpio Therapeutics Overall, Kearny Venture Partners portfolio has seen 8 IPOs and 10 acquisitions including key companies like Tandem Diabetes, CVRx and Akebia Therapeutics. A lot of funds co-invest with Kearny Venture Partners, with names like InterWest Partners sharing a substantial percentage of its portfolio. Kearny Venture Partners has team of 7 people including 5 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series B, Series A & 2 more
Portfolio IPOs
Portfolio Acquisitions
Kearny Venture Partners' List of Top Investments
Kearny Venture Partners has a portfolio of 23 companies. Their most notable investments are in Aerpio Therapeutics and Boreal Genomics.Their portfolio spans across United States and Germany. They have invested in Life Sciences, High Tech, Enterprise Applications and 1 other sectors, across stages such as Series B, Series A and 2 more. Here is the list of top investments by Kearny Venture Partners:Tandem Diabetes is a developer of devices for continuous glucose monitoring and manual insulin delivery. It develops insulin pumps & other products and services that bring innovation, convenience & style to diabetes management. The first product, the t: slim Insulin Pump, features a sleek, modern design, intuitive touch-screen interface, and a rechargeable lithium-polymer battery. The company claims that this makes them closer to producing a fully automated closed-loop automated insulin delivery device that will not require human intervention to release insulin.
Key facts about Tandem Diabetes
- Founded Year: 2008
- Location: San Diego (United States)
- Annual Revenue: $1B+ as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $101M
- Employee Count: 2,198 as on May 31, 2026
- Investors: Gynther Capital, Domain Associates and 5 Others
- Latest Funding Round: Post IPO, May 15, 2020, $*****
- Highlight: Public
2. CVRx
CVRx is a developer of implantable technology for hypertension and heart failure. The product Barostim neo is implanted under the skin, similar to a pacemaker. It then sends signals to the body's cardiovascular regulators to improve cardiac and vascular function by restoring sympathovagal balance through activation of the afferent and efferent pathways of the autonomic nervous system. The product is CE marked and approved for sale in Europe for both indications.
Key facts about CVRx
- Founded Year: 2001
- Location: Minneapolis (United States)
- Annual Revenue: $50M - $100M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $394M
- Employee Count: 255 as on May 31, 2026
- Investors: Gilde Healthcare, Piper Jaffray and 20 Others
- Latest Funding Round: Series F, Jul 07, 2020, $*****
- Highlight: Public
Developing therapeutics solutions to treat patients with kidney disease. The company's lead candidate is Vafseo is approved as a treatment for anemia due to CKD in both dialysis-dependent and non-dialysis dependent adult patients.
Key facts about Akebia Therapeutics
- Founded Year: 2007
- Location: Cincinnati (United States)
- Annual Revenue: $100M - $500M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $91M
- Employee Count: 270 as on May 31, 2026
- Investors: Longitude Capital, Novo Holdings and 13 Others
- Latest Funding Round: Conventional Debt, Jan 30, 2024, $*****
- Highlight: Public
4. Trivascular
TriVascular is a company that designs and manufactures endovascular aortic repair equipment. It offers Ovation Abdominal Stent Graft System that assists in profiling of endovascular graft for the treatment of abdominal aortic aneurysms. The system is FDA-approved.
Key facts about Trivascular
- Founded Year: 1998
- Location: Santa Rosa (United States)
- Annual Revenue: $10M - $50M as on Dec 31, 2014
- Stage: Public
- Total Funding till date: $261M
- Employee Count: 307 as on Dec 31, 2014
- Investors: Kaiser Permanente Ventures, Redmile Group and 6 Others
- Latest Funding Round: Post IPO, Aug 20, 2015, $*****
- Highlight: Public
Manufacturer of MRI-guided radiation therapy systems for cancer treatment. The systems offer diagnostic-quality MRI imaging, precise contouring, real-time tissue tracking, and automated beam control. These features ensure accurate dose delivery to the target. The systems are used for pancreas, prostate, lung, liver, breast, and oligometastatic cancers.
Key facts about Viewraysystems
- Founded Year: 2004
- Location: Lage (Germany)
- Annual Revenue: $100M - $500M as on Dec 31, 2022
- Stage: Public
- Total Funding till date: $177M
- Employee Count: 80 as on May 31, 2026
- Investors: Fidelity Investments, Hercules Capital and 12 Others
- Latest Funding Round: Post IPO, Dec 17, 2018, $*****
- Highlight: Public
Kearny Venture Partners' Investments by Stage
Kearny Venture Partners has made 4 investments in Series B stage with an average round size of $18M, 3 investments in Series A stage with an average round size of $31.3M, 2 investments in Series C stage with an average round size of $37.6M and 1 investment in Series D stage with an average round size of $60M.Stage of entry | No. of Investments |
|---|---|
Series B | 4 |
Series A | 3 |
Series C | 2 |
Series D | 1 |
Note: We have considered here, only first round of investments
Kearny Venture Partners' Investments by Sector
Kearny Venture Partners has a diverse portfolio, with companies operating in the Life Sciences, Enterprise Applications, Consumer and High Tech. Notably, it has invested in 19 Tech companies, 14 Enterprise (B2B) companies, 7 Software companies and at least 6 companies focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Life Sciences | 10 |
Enterprise Applications | 2 |
Consumer | 1 |
High Tech | 1 |
Note: We have considered here, only first round of investments
Kearny Venture Partners' Investments by Geography
Kearny Venture Partners has made most investments in United States (8), followed by Germany where it has made 2 investments.Country | No. of Investments |
|---|---|
United States | 8 |
Germany | 2 |
Note: We have considered here, only first round of investments
Kearny Venture Partners' recent investments
Kearny Venture Partners has not made any investment in 2026 so far.Here are the most recent investments by Kearny Venture Partners:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Mar 16, 2017 | United States | Series C | 1169 | ||
Feb 02, 2017 | Germany | Post IPO | 8323 | [+1] | |
Aug 17, 2015 | Germany | Post IPO | 7325 | [+4] | |
May 06, 2014 | United States | Series B | 8211 | [+4] | |
Dec 17, 2013 | Germany | Series D | 9656 | [+3] |
IPOs and Publicly Listed companies in Kearny Venture Partners' Portfolio
8 of Kearny Venture Partners' portfolio companies have become public. CVRx got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Jun 2021 at marketcap of $126M and Aerpio Therapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ).Here are Kearny Venture Partners' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jun 30, 2021 | May 11, 2006 | Series C | 9838 | |
Aug 09, 2017 | Nov 06, 2013 | Series A | 1639 | |
Aug 14, 2015 | Apr 14, 2008 | Series B | 4511 | |
Apr 15, 2014 | Jun 04, 2012 | Series D | 6950 | |
Mar 20, 2014 | Jun 16, 2010 | Series A | 9881 |
Acquired companies in Kearny Venture Partners' Portfolio
10 companies from Kearny Venture Partners' portfolio have been acquired. The most recent acquisition was NextWave Pharmaceuticals in Sep 2018 by Tris Pharma for $*****.Here are Kearny Venture Partners' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Sep 25, 2018 | Jan 12, 2011 | Series C | 1629 | |
Dec 12, 2017 | - | - | 4153 | |
Aug 22, 2016 | - | - | 9484 | |
Apr 20, 2016 | - | - | 4743 | |
Apr 23, 2012 | - | - | 4768 |
Team profile of Kearny Venture Partners
Kearny Venture Partners has a team of 7 members including 5 Partners and 1 Venture Partner located in United States. Kearny Venture Partners' team does not sit on the board of any company as of now.Here is a list of all team members in Kearny Venture Partners:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | San Francisco | - | ||
Partner | San Francisco | - | ||
Partner | San Francisco | - | ||
Partner | San Francisco | - | ||
Partner | San Francisco | - | - | |
Venture Partner | San Francisco | - | - |
Co-investors of Kearny Venture Partners
Over the past 22 years, 73 investors have co-invested in Kearny Venture Partners's portfolio companies. This includes funds and angels.
- Invested before Kearny Venture Partners: New Enterprise Associates, Piper Jaffray and 5 others have invested in rounds before Kearny Venture Partners. There are 2 companies where New Enterprise Associates has invested before Kearny Venture Partners and 1 company where Piper Jaffray has invested before Kearny Venture Partners.
- Top Co-investors of Kearny Venture Partners: 27 investors entered a company along with Kearny Venture Partners. These include investors like InterWest Partners (2 companies).
- Invested after Kearny Venture Partners: A total of 39 investors have invested in Kearny Venture Partners's portfolio after their investments. Top Investors include Genechem (2 companies), Montrose Capital Partners (2 companies) and Johnson & Johnson Innovation (1 company).
Recent News related to Kearny Venture Partners
•
NAI James E. Hanson Negotiates Sale of 6,500- Sf Industrial Building in Hackensack, N.JReal Estate Weekly•Feb 03, 2022•NAI James E. Hanson, Kearny Venture Partners
•
Aerpio Pharmaceuticals Announces Results From TIME-2b Study of AKB-9778 in Diabetic RetinopathyBusiness Wire•Mar 18, 2019•Aerpio Therapeutics, Novartis Venture Fund, Orbimed, Kearny Venture Partners and 3 others
•
Aerpio Pharmaceuticals Raises $40M from NovartisCitybizlist•Mar 16, 2017•Aerpio Therapeutics, Akebia Therapeutics, Novartis Venture Fund, Orbimed and 4 others
•
CVRx®, Inc. Closes $84 Million FinancingCVRx•Jul 29, 2008•CVRx, New Enterprise Associates, JJDC, InterWest Partners and 4 others
•
CVRx Raises Additional $30 MillionCVRx•May 11, 2006•CVRx, New Enterprise Associates, InterWest Partners, ABS Ventures and 3 others
•
•
Aspreva Pharmaceuticals Completes First-Round Private Equity Financing, Raising US$57 Million | Business WireBusiness Wire•Mar 09, 2004•Aspreva Pharmaceutics, InterWest Partners, HBM Partners, Axiom Venture Partners and 3 others
•
•
•
The Business Journals•Baxano, Kearny Venture Partners, Prospect Venture Partners, Three Arch Partners
